QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

OPK

QT59OPKO Health, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
1.42
+0.01+0.71%
OverviewShort InterestFilings
OPKQT59OPKO Health, Inc.·NASDAQ
OverviewShort InterestFilings
1.42+0.71%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.28
Insider Own-
Shs Outstand755.09M
Perf Week-2.07%
Market Cap1.06BForward P/E-EPS next Y-0.26Insider Trans0.00%Shs Float-Perf Month23.48%
Enterprise Value1.12BPEG0.02EPS next Q-0.08Inst Own-Short Float-Perf Quarter21.37%
Income-211871336.00P/S1.83EPS this Y-9.18%Inst Trans-Short Ratio-Perf Half Y8.40%
Sales581.13MP/B0.89EPS next Y13.55%ROA-11.47%Short Interest-Perf YTD12.70%
Book/sh1.60P/C-EPS next 5Y-ROE-16.78%52W High1.60 -11.25%Perf Year10.08%
Cash/sh0.45P/FCF-EPS past 3/5Y-ROIC-10.90%52W Low0.98 45.36%Perf 3Y-
Dividend Est.-EV/EBITDA-32.27Sales past 3/5Y-15.44% -15.81%Gross Margin22.73%Volatility2.63% 3.37%Perf 5Y-
Dividend TTM-EV/Sales1.93EPS Y/Y TTM-252.02%Oper. Margin-34.90%ATR (14)0.06Perf 10Y-
Dividend Ex-Date-Quick Ratio3.17Sales Y/Y TTM-18.51%Profit Margin-36.64%RSI (14)62.16Recom2.46
Dividend Gr. 3/5Y-Current Ratio3.61EPS Q/Q30.00%SMA201.46%Beta1.03Target Price2.87
Payout0.00%Debt/Eq0.33Sales Q/Q-17.33%SMA5013.02%Rel Volume2.06Prev Close1.41
Employees2,997LT Debt/Eq0.32EarningsJul 30SMA2008.67%Avg Volume2.54MPrice1.42
IPO DateNov 02, 1995Option/ShortNo / YesEPS/Sales Surpr.0.00% -5.34%Net Debt/EBITDA-1.59Volume5,230,240Change0.71%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-29-26DowngradeBarrington ResearchOutperform → Market Perform
Oct-31-25DowngradeJefferiesBuy → Hold$1.60
Jun-29-23UpgradeBarrington ResearchMarket Perform → Outperform
Dec-15-22InitiatedH.C. Wainwright$3.00
Jan-24-22DowngradeBarrington ResearchOutperform → Market Perform
Mar-02-18DowngradeJP MorganNeutral → Underweight
Sep-14-17DowngradeJP MorganOverweight → Neutral
Mar-03-15DowngradeOppenheimerOutperform → Perform
Latest News
Jun-16-26
Jun-16-2608:44AM
Entera Bio Reports Preclinical Results For Oral Peptide Programs EB612 And EB618, Advancing Toward Clinical DevelopmentBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue581607713
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A448479402
Gross Profit132128311
Selling, General and Administrative Excl. Other214223304
Research and Development122124105
Other Operating Expense-1054
Operating Income-203-219-152
Interest Expense10310847
Unusual Expense
———
Non-Operating Income (Expense)-78-86-189
Net Income Before Taxes-230-241-10
Income Taxes-16-1643
Consolidated Net Income-212-226-53
Net Income From Continuing Operations-212-226-53
Net Income-212-226-53
EPS (Recurring)-0.28-0.30-0.08
EPS (Basic, Before Extraordinaries)-0.28-0.30-0.08
EPS (Diluted)-0.28-0.30-0.08
EBITDA-34-41135
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio1.861.56—
Gross Margin22.7221.0943.62
Operating Margin-34.94-36.08-21.32
Net Margin-36.49-37.23-7.43
Shares Outstanding759751694
Market Capitalization1,078946—
Operating Lease Expense
———
Insider Trading Volume
$1.50$1.33$1.17$1.00$0.83● Close Price0.00M0.74M1.49M2.23M2.98MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
PAGANELLI JOHN ADirectorMar 20 '26Buy1.1410,00011,350394,340Mar 20 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanNov 21 '25Buy1.33580,000768,807216,706,448Nov 21 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanNov 20 '25Buy1.33580,000771,327216,126,448Nov 20 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanNov 19 '25Buy1.31580,000759,117215,546,448Nov 19 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanNov 18 '25Buy1.27533,300678,905214,966,448Nov 18 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanOct 31 '25Buy1.42150,000213,435214,386,448Oct 31 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanAug 08 '25Buy1.32675,000891,000214,676,448Aug 08 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanApr 10 '25Buy1.36125,000169,713214,001,448Apr 10 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanApr 08 '25Buy1.48125,000184,650213,876,448Apr 08 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanApr 01 '25Buy1.65100,000164,850213,751,448Apr 01 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanMar 28 '25Buy1.70150,000254,385213,651,448Mar 28 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanMar 17 '25Buy1.74200,000347,820213,501,448Mar 17 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanMar 04 '25Buy1.15000Mar 04 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanMar 03 '25Buy1.15000Mar 03 12:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanFeb 28 '25Buy1.7167,434115,312213,301,448Feb 28 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR